Deutsch English Français

Contact

EP1098664

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1098664

EP1098664 - CONJUGATES FOR TREATING INFLAMMATORY DISORDERS AND ASSOCIATED TISSUE DAMAGE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 11.06.2004 Database last updated on 14.09.2024
Most recent event Tooltip	04.05.2007	Lapse of the patent in a contracting state New state(s): CY	published on 06.06.2007 [2007/23]
Applicant(s)	For all designated states Osprey Pharmaceuticals Limited 3400 Petro-Canada Centre, 150-6th Avenue SW Calgary Alberta T2P 3Y7 / CA
	[N/P]
Former [2001/20]	For all designated states Osprey Pharmaceuticals Limited 3400 Petro-Canada Centre, 150-6th Avenue SW Calgary, Alberta T2P 3Y7 / CA
Inventor(s)	01 / MCDONALD, John, R. 60 Governor Drive SW Calgary, Alberta T3E 4Y9 / CA
	02 / COGGINS, Philip, J. 4211, 5A Street SW Calgary, Alberta T2S 2G8 / CA
	[2001/20]
Representative(s)	Baldock, Sharon Claire, et al Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
	[N/P]
Former [2001/20]	Baldock, Sharon Claire, et al BOULT WADE TENNANT, Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Application number, filing date	99932572.3	21.07.1999
	[2001/20]
	WO1999CA00659
Priority number, date	US19980120523	22.07.1998 Original published format: US 120523
	[2001/20]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0004926
	Date:	03.02.2000
	Language:	EN
	[2000/05]
	Type:	A2 Application without search report
	No.:	EP1098664
	Date:	16.05.2001
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 03.02.2000 takes the place of the publication of the European patent application.
	[2001/20]
	Type:	B1 Patent specification
	No.:	EP1098664
	Date:	06.08.2003
	Language:	EN
	[2003/32]
Search report(s)	International search report - published on:	EP	02.11.2000
Classification	IPC:	A61K47/48, A61K48/00, C12N15/19, C12N15/62, C12N15/29, C12N15/31, C07K14/52, C07K19/00, C07K14/415, A61P29/00	[2002/44]
	CPC:	A61K48/0033 (EP); A61K47/62 (EP); A61K47/642 (EP); A61K47/6425 (EP); A61K47/6811 (EP); A61P1/04 (EP); (+) A61P11/00 (EP); A61P11/02 (EP); A61P13/12 (EP); A61P19/02 (EP); A61P25/00 (EP); A61P25/16 (EP); A61P25/28 (EP); A61P27/02 (EP); A61P29/00 (EP); A61P35/00 (EP); A61P37/08 (EP); A61P43/00 (EP); A61P5/14 (EP); A61P9/04 (EP); A61P9/10 (EP); C07K14/522 (EP); C07K14/523 (EP); C07K2319/00 (EP) (-)
	Former IPC [2001/20]	A61K47/48, A61K48/00, C12N15/19, C12N15/62, C12N15/29, C12N15/31, C07K14/52, C07K19/00, C07K14/415
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2001/20]
Extension states	AL	15.01.2001
	LT	15.01.2001
	LV	15.01.2001
	MK	15.01.2001
	RO	15.01.2001
	SI	15.01.2001
Title	German:	KONJUGATE ZUR BEHANDLUNG VON ENTZÜNDUNGSKRANKHEITEN UND VON ASSOZIERTER GEWEBESCHÄDIGUNG	[2001/20]
	English:	CONJUGATES FOR TREATING INFLAMMATORY DISORDERS AND ASSOCIATED TISSUE DAMAGE	[2001/20]
	French:	TRAITEMENT DE DEGATS TISSULAIRES SECONDAIRES, ETATS INFLAMMATOIRES ET AUTRES TROUBLES, ET COMPOSITIONS A CET EFFET	[2001/20]
Entry into regional phase	15.01.2001	National basic fee paid
	15.01.2001	Designation fee(s) paid
	15.01.2001	Examination fee paid
Examination procedure	10.01.2000	Request for preliminary examination filed International Preliminary Examining Authority: EP
	15.01.2001	Amendment by applicant (claims and/or description)
	15.01.2001	Examination requested [2001/20]
	10.04.2002	Despatch of a communication from the examining division (Time limit: M04)
	20.08.2002	Reply to a communication from the examining division
	03.09.2002	Despatch of a communication from the examining division (Time limit: M01)
	04.09.2002	Reply to a communication from the examining division
	11.11.2002	Communication of intention to grant the patent
	09.05.2003	Fee for grant paid
	09.05.2003	Fee for publishing/printing paid
Divisional application(s)	EP03076150.6 / EP1346731
Opposition(s)	07.05.2004	No opposition filed within time limit [2004/31]
Fees paid	Renewal fee
	09.03.2001	Renewal fee patent year 03
	11.03.2002	Renewal fee patent year 04
	31.03.2003	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	CY	06.08.2003
	FI	06.08.2003
	PT	06.01.2004
	[2007/23]
Former [2004/31]	FI	06.08.2003
	PT	06.01.2004
Former [2004/12]	FI	06.08.2003
Cited in	International search	[X]WO9012597 (SALK INST FOR BIOLOGICAL STUDI [US]) [X] 50-53,58 * page 3, line 3 - line 22 *;
		[A]WO9118012 (BIOSPAN CORP [US]) [A] 1-79 * the whole document *;
		[X]US5084556 (BROWN EUGENE L [US]) [X] 50-53,64 * column 5, line 31 - column 5, line 42 *;
		[X]US5152980 (STROM TERRY B [US], et al) [X] 50-64,67-71,76-78* column 1, line 41 - line 52 *;
		[A]WO9323062 (IMMUNOMEDICS INC [US]) [A] 1-79 * the whole document *;
		[X]WO9325228 (WHITTIER INST DIABETES & ENDOC [US], et al) [X] 50-64,67-71,76-78 * page 4, line 6 - line 29 * * page 18, line 9 - line 15 *;
		[X]WO9407535 (MALLINCKRODT MEDICAL INC [US], et al) [X] 1-43,65,73-75 * examples 1-8 *;
		[X]WO9407542 (MALLINCKRODT MEDICAL INC [US], et al) [X] 1-43,65,73-75 * examples 1-8 *;
		[X]US5326559 (MILLER D DOUGLAS [US]) [X] 50-64,67-71,76-78 * column 4, line 37 - line 41 * * column 8, line 3 - line 17 * * column 11, line 67 - line 68 *;
		[X]WO9512414 (REPLIGEN CORP [US]) [X] 1-47,65,73-75,79 * example 26 * * claims 16-22 * * page 9, line 31 - page 10, line 9 *;
		[X] - P ROBY ET AL, "Melanoma-specific cytotoxicity of a human MGSA/GROalpha C-terminal peptide conjugated to daunorubicin", ONCOLOGY REPORTS, (1996), vol. 3, pages 175 - 179, XP000881561 [X] 1-43,65,73-75 * abstract * * "Cytotoxicity..Etc" on pages 177 to 178 * * discussion *
		[X] - D I SILBERT, "Glycosaminoglycans of bovine aorta endothelial cells: Identification and localization by use of a platelet factor 4-fluorescein probe", JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, (1990), vol. 38, no. 4, pages 589 - 593, XP000881557 [X] 1-43,65,73-75 * abstract *
		[X] - E RAY ET AL, "Receptor mediated endocytosis of IL-8: a fluorescent microscopic evidence and implication of the process in ligand induced biological response in human neutrophils", CYTOKINE, 1997, (199708), vol. 9, no. 8, pages 587 - 596, XP000881538 [X] 1-43,65,73-75 * abstract * DOI: http://dx.doi.org/10.1006/cyto.1997.0206
		[X] - RALPH, P., "Clinical and preclinical studies presented by the keystone symposium on arthritis", LYMPHOKINE AND CYTOKINE RESEARCH, (199308), vol. 12, no. 4, pages 261 - 263, XP000891639 [X] 50-64,67-71,76-78 * abstract * * page 262, column 1, line 29 - line 47 *
		[X] - STROM, TERRY B. ET AL, "Interleukin-2 receptor-directed therapies: Antibody- or cytokine-based targeting molecules", ANNU. REV. MED. (1993), 44, 343-53, XP000915772 [X] 50-64,67-71,76-78 * page 347 - page 351 *
		[X] - NAGPAL, SUNIL ET AL, "New dermatological agents for the treatment of psoriasis", ANNU. REP. MED. CHEM. (1997), 32, 201-210, XP000915751 [X] 50-64,67-71,76-78 * "Introduction" on page 201 and the "New targets" on page 207 to 208 with reference to "fusion proteins" *
		[X] - ROBERGE, FRANCOIS G. ET AL, "Selective immunosuppression of activated T cells with the chimeric toxin IL - 2 -PE40. Inhibition of experimental autoimmune uveoretinitis", J. IMMUNOL. (1989), 143(11), 3498-502, XP002028689 [X] 50-64,67-71,76-78 * abstract *
		[X] - SHEMYAKIN, I. G. ET AL, "Construction and expression in Escherichia coli cells of the fusion protein diphtheria toxin -human interleukin 2", CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 119:40509, URL: STN, XP002141203 [X] 50-54 * abstract *
		[ ] - MOL. BIOL. (MOSCOW) (1992), 26(5), 1088-98
		[X] - HUSAIN, SYED R. ET AL, "Complete regression of established human glioblastoma tumor xenograft by interleukin -4 toxin therapy", CANCER RES. (1998), 58(16), 3649-3653, XP000910254 [X] 50-53,64 * abstract *
		[X] - MENEGHETTI, CAROLE M. ET AL, "Initial clinical experiences with an interleukin -2 fusion toxin (DAB486- IL - 2 )", TARGETED DIAGN. THER. (1992), 7(GENET. ENG. TOXINS), 395-401, XP000915730 [X] 50-53,64 * "III the chimeric fusion protein..Etc" on pages 396 to 399 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p